1. Market Research
  2. > Chemotherapy Effects - Pipeline Review, H2 2013

Chemotherapy Effects - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 131 pages

Chemotherapy Effects - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Chemotherapy Effects - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Effects, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Effects. Chemotherapy Effects - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Effects.
- A review of the Chemotherapy Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Effects pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Effects.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Effects pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Chemotherapy Effects - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Effects Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Chemotherapy Effects 11
Chemotherapy Effects Therapeutics under Development by Companies 13
Chemotherapy Effects Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Chemotherapy Effects Therapeutics - Products under Development by Companies 21
Chemotherapy Effects Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Chemotherapy Effects Therapeutics Development 24
Adherex Technologies Inc. 24
Lentigen Corporation 25
Sigma-Tau S.p.A. 26
CEL-SCI Corporation 27
Hana Biosciences, Inc. 28
La Jolla Pharmaceutical Company 29
Telik, Inc. 30
LG Life Sciences, Ltd 31
Pluristem Therapeutics Inc. 32
BioAlliance Pharma SA 33
Spectrum Pharmaceuticals, Inc. 34
Helsinn Healthcare S.A. 35
Wellstat Therapeutics Corporation 36
Ventria Bioscience 37
PledPharma AB 38
Tranzyme Pharma, Inc. 39
ProCertus BioPharm Inc. 40
Indus Biotech Private Limited 41
Sound Pharmaceuticals, Inc. 42
SpePharm Holding B.V. 43
Neumedicines Inc. 44
Applied Protein Sciences, LLC 45
Chemotherapy Effects - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
Sodium Thiosulfate - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
menadione - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
clonidine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Leukocyte Interleukin Injection - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
TZP-201 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
ezatiostat hydrochloride - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
LG-631 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
elsiglutide - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
INDUS-82020 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
levoleucovorin calcium - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
GCS-100 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
MTP-131 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
dexrazoxane - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
minocycline - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
CR-3294 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
uridine triacetate - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
SPI-1005 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
SPI-3005 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
NMIL-121 - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
C-31510 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
arsenic trioxide - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
Acetyl-L-Carnitine - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
budesonide - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
PLX-BMP - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
calcitriol - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
PLED-mangafodipir trisodium - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
NecroX-7 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
VEN-101 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
AP-002 - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
AP-001 - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
Apoptosis Inhibitors - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
MT-004 - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
OralX - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
Chemotherapy Effects Therapeutics - Drug Profile Updates 97
Chemotherapy Effects Therapeutics - Discontinued Products 121
Chemotherapy Effects Therapeutics - Dormant Products 122
Chemotherapy Effects - Product Development Milestones 123
Featured News and Press Releases 123
May 28, 2013: Helsinn And Zealand Pharma Announce Decision To Advance Development Of Elsiglutide Into Phase IIb For Prevention Of Chemotherapy-induced Diarrhea 123
Feb 26, 2013: PledPharma Receives DSMB Approval To Continue Patient Recruitment In Phase II Study Of PledOx 124
Feb 14, 2013: BioAlliance Pharma Announces Forthcoming Extension Of Its Phase II Clinical Trial With Validive In US 124
Feb 12, 2013: Recipharm Supplies Clinical Trial Material For FDA Approved Phase IIb Study Sponsored By PledPharma 125
Jan 30, 2013: Kissei Pharma Announces Filing Of New Drug Application For Dexrazoxane In Japan 125
Jan 22, 2013: New Drug Protects Against Side Effects Of Chemotherapy, Researchers Report 126
Jan 22, 2013: PledPharma Receives FDA Approval For Phase IIb Trial Of PledOx 126
Dec 27, 2012: PledPharma's PledOx Shows Superior Ability To Reduce Chemotherapy Side Effects, New Study Finds 127
Sep 05, 2012: CMS Grants New Prospective Reimbursement For BTG's Voraxaze 128
Apr 02, 2012: Researchers From University Of Pittsburgh's Cancer Institute And School Of Medicine Gain Better Understanding Of Radiation-Mitigator Drug 129
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 131
Disclaimer 131

List of Tables

Number of Products Under Development for Chemotherapy Effects, H2 2013 11
Products under Development for Chemotherapy Effects - Comparative Analysis, H2 2013 12
Number of Products under Development by Companies, H2 2013 14
Number of Products under Development by Companies, H2 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2013 16
Comparative Analysis by Late Stage Development, H2 2013 17
Comparative Analysis by Mid Clinical Stage Development, H2 2013 18
Comparative Analysis by Early Clinical Stage Development, H2 2013 19
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Development by Companies, H2 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2013 23
Adherex Technologies Inc., H2 2013 24
Lentigen Corporation, H2 2013 25
Sigma-Tau S.p.A., H2 2013 26
CEL-SCI Corporation, H2 2013 27
Hana Biosciences, Inc., H2 2013 28
La Jolla Pharmaceutical Company, H2 2013 29
Telik, Inc., H2 2013 30
LG Life Sciences, Ltd, H2 2013 31
Pluristem Therapeutics Inc., H2 2013 32
BioAlliance Pharma SA, H2 2013 33
Spectrum Pharmaceuticals, Inc., H2 2013 34
Helsinn Healthcare S.A., H2 2013 35
Wellstat Therapeutics Corporation, H2 2013 36
Ventria Bioscience, H2 2013 37
PledPharma AB, H2 2013 38
Tranzyme Pharma, Inc., H2 2013 39
ProCertus BioPharm Inc., H2 2013 40
Indus Biotech Private Limited, H2 2013 41
Sound Pharmaceuticals, Inc., H2 2013 42
SpePharm Holding B.V., H2 2013 43
Neumedicines Inc., H2 2013 44
Applied Protein Sciences, LLC, H2 2013 45
Assessment by Monotherapy Products, H2 2013 46
Assessment by Stage and Route of Administration, H2 2013 48
Assessment by Stage and Molecule Type, H2 2013 50
Chemotherapy Effects Therapeutics - Drug Profile Updates 97
Chemotherapy Effects Therapeutics - Discontinued Products 121
Chemotherapy Effects Therapeutics - Dormant Products 122

List of Figures

Number of Products under Development for Chemotherapy Effects, H2 2013 11
Products under Development for Chemotherapy Effects - Comparative Analysis, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 16
Late Stage Products, H2 2013 17
Mid Clinical Stage Products, H2 2013 18
Early Clinical Stage Products, H2 2013 19
Pre-Clinical Stage Products, H2 2013 20
Assessment by Monotherapy Products, H2 2013 46
Assessment by Route of Administration, H2 2013 47
Assessment by Stage and Route of Administration, H2 2013 48
Assessment by Molecule Type, H2 2013 49
Assessment by Stage and Molecule Type, H2 2013 50

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.